ANAPTYSBIO INC (ANAB) Stock Price, Quote, News and Overview
NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock - Currency: USD
ANAB Quote, Performance and Key Statistics
21.58
+0.96 (+4.66%)
The current stock price of ANAB is 21.58 USD. In the past month the price increased by 15.34%. In the past year, price increased by 2.76%.
ANAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.17 | 307.41B | ||
| AMGN | AMGEN INC | 14.05 | 149.68B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.53B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1691.28 | 126.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 64.01B | ||
| ARGX | ARGENX SE - ADR | 322.51 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.80B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.17B | ||
| NTRA | NATERA INC | N/A | 19.55B | ||
| BIIB | BIOGEN INC | 7.22 | 17.40B |
Related stock screener links
About ANAB
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The firm's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Company Info
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 117
Company Website: https://www.anaptysbio.com/
Investor Relations: https://ir.anaptysbio.com/
Phone: 18583626295
ANAPTYSBIO INC / ANAB FAQ
What is the stock price of ANAPTYSBIO INC today?
The current stock price of ANAB is 21.58 USD. The price increased by 4.66% in the last trading session.
What is the ticker symbol for ANAPTYSBIO INC stock?
The exchange symbol of ANAPTYSBIO INC is ANAB and it is listed on the Nasdaq exchange.
On which exchange is ANAB stock listed?
ANAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANAPTYSBIO INC stock?
18 analysts have analysed ANAB and the average price target is 37.94 USD. This implies a price increase of 75.83% is expected in the next year compared to the current price of 21.58. Check the ANAPTYSBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANAPTYSBIO INC worth?
ANAPTYSBIO INC (ANAB) has a market capitalization of 661.86M USD. This makes ANAB a Small Cap stock.
How many employees does ANAPTYSBIO INC have?
ANAPTYSBIO INC (ANAB) currently has 117 employees.
What are the support and resistance levels for ANAPTYSBIO INC (ANAB) stock?
ANAPTYSBIO INC (ANAB) has a support level at 18.79 and a resistance level at 21.59. Check the full technical report for a detailed analysis of ANAB support and resistance levels.
Is ANAPTYSBIO INC (ANAB) expected to grow?
The Revenue of ANAPTYSBIO INC (ANAB) is expected to decline by -12.34% in the next year. Check the estimates tab for more information on the ANAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ANAPTYSBIO INC (ANAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANAB, evaluating the profitability, health, valuation and growth aspects
- ANAPTYSBIO INC (ANAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANAPTYSBIO INC (ANAB) Sales and EPS estimates to see what analysts future expectations are.
- ANAPTYSBIO INC (ANAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANAPTYSBIO INC (ANAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANAPTYSBIO INC (ANAB) Stock Chart to make your own analysis
- ANAPTYSBIO INC (ANAB) Latest news and press-releases to stay up to date.
Does ANAPTYSBIO INC (ANAB) stock pay dividends?
ANAB does not pay a dividend.
When does ANAPTYSBIO INC (ANAB) report earnings?
ANAPTYSBIO INC (ANAB) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ANAPTYSBIO INC (ANAB)?
ANAPTYSBIO INC (ANAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.21).
What is the Short Interest ratio of ANAPTYSBIO INC (ANAB) stock?
The outstanding short interest for ANAPTYSBIO INC (ANAB) is 31.34% of its float. Check the ownership tab for more information on the ANAB short interest.
ANAB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANAB. When comparing the yearly performance of all stocks, ANAB is one of the better performing stocks in the market, outperforming 90.1% of all stocks.
ANAB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ANAB. While ANAB has a great health rating, there are worries on its profitability.
ANAB Financial Highlights
Over the last trailing twelve months ANAB reported a non-GAAP Earnings per Share(EPS) of -5.21. The EPS increased by 14.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.02% | ||
| ROE | -204.93% | ||
| Debt/Equity | 0 |
ANAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ANAB. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -1.52% and a revenue growth -12.34% for ANAB